Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease.
Omega-3 polyunsaturated fatty acids as a treatment strategy for nonalcoholic fatty liver disease.
复制标题
DOI：
10.1016/j.pharmthera.2017.07.007
复制
发表时间：
2018-01
影响因子：
13.5
通讯作者：
Tripathy S
中科院分区：
文献类型：
--
作者：
Jump DB;Lytle KA;Depner CM;Tripathy S
肥胖和 2 型糖尿病 (T2DM) 患者非酒精性脂肪肝 (NAFLD) 的患病率很高。 NAFLD 是一系列慢性肝病，从良性肝脂肪变性到非酒精性脂肪性肝炎 (NASH)、肝硬化和原发性肝细胞癌 (HCC)。由于 NAFLD 与肥胖流行密切相关，NAFLD 正迅速成为全球主要的公共卫生问题。令人惊讶的是，目前还没有 FDA 批准的 NAFLD 疗法；目前的治疗重点是与 NAFLD 相关的合并症，即肥胖、高血糖、血脂异常和高血压。本次综述的目的是提供疾病过程的背景，讨论研究治疗方案的人体研究和临床前模型。我们还提供了使用膳食 ω3 多不饱和脂肪酸 (ω3 PUFA) 补充剂作为 NAFLD 治疗选择的深入原理。这一重点基于最近的研究表明 NASH 患者和 NASH 临床前小鼠模型的肝脏 C20-22 ω3 PUFA 水平较低。肝脏 PUFA 的下降可能是与 NASH 相关的主要表型特征的原因，包括脂肪变性、炎症和纤维化。最后，我们的讨论将讨论 ω3 PUFA 补充剂在 NAFLD 治疗中的优点和局限性。
Obese and type 2 diabetic (T2DM) patients have a high prevalence of nonalcoholic fatty liver disease (NAFLD). NAFLD is a continuum of chronic liver diseases ranging from benign hepatosteatosis to nonalcoholic steatohepatitis (NASH), cirrhosis and primary hepatocellular cancer (HCC). Because of its strong association with the obesity epidemic, NAFLD is rapidly becoming a major public health concern worldwide. Surprisingly, there are no FDA approved NAFLD therapies; and current therapies focus on the co-morbidities associated with NAFLD, namely, obesity, hyperglycemia, dyslipidemia, and hypertension. The goal of this review is to provide background on the disease process, discuss human studies and preclinical models that have examined treatment options. We also provide an in-depth rationale for the use of dietary ω3 polyunsaturated fatty acid (ω3 PUFA) supplements as a treatment option for NAFLD. This focus is based on recent studies indicating that NASH patients and preclinical mouse models of NASH have low levels of hepatic C20-22 ω3 PUFA. This decline in hepatic PUFA may account for the major phenotypic features associated with NASH, including steatosis, inflammation and fibrosis. Finally, our discussion will address the strengths and limitations of ω3 PUFA supplements use in NAFLD therapy.
登录
查看更多内容
影响因子：
7.7
作者：
Cani, Patrice D.;Amar, Jacques;Burcelin, Remy
通讯作者：
Burcelin, Remy
影响因子：
2.5
作者：
Banini BA;Sanyal AJ
通讯作者：
Sanyal AJ
影响因子：
25.7
作者：
Allard, Johane P.;Aghdassi, Elaheh;Heathcote, Jenny E.
通讯作者：
Heathcote, Jenny E.
影响因子：
7.1
作者：
Allaire, Janie;Couture, Patrick;Lamarche, Benoit
通讯作者：
Lamarche, Benoit
DOI：
10.1016/j.bpg.2014.08.007
发表时间：
2014-10-01
影响因子：
3.2
作者：
Bosetti, Cristina;Turati, Federica;La Vecchia, Carlo
通讯作者：
La Vecchia, Carlo